ATNM Stock Performance, Insider Transaction and News

ATNM - Actinium Pharmaceuticals, Inc.

Market Cap	184.87M	P/E	-	EPS this Y	-4.90%	Ern Qtrly Grth	-
Income	-48.82M	Forward P/E	-5.04	EPS next Y	94.30%	50D Avg Chg	-9.00%
Sales	81k	PEG	-	EPS past 5Y	-	200D Avg Chg	-27.00%
Dividend	N/A	Price/Book	3.15	EPS next 5Y	-	52W High Chg	-54.00%
Recommedations	2.00	Quick Ratio	9.03	Shares Outstanding	29.40M	52W Low Chg	35.00%
Insider Own	2.16%	ROA	-33.17%	Shares Float	28.61M	Beta	0.08
Inst Own	24.63%	ROE	-94.92%	Shares Shorted/Prior	1.98M/1.82M	Price	7.00
Gross Margin	100.00%	Profit Margin	-	Avg. Volume	222,606	Target Price	25.47
Oper. Margin	-12,769.14%	Earnings Date	May 15	Volume	107,766	Change	-1.96%

Healthcare | Biotechnology | United States

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, Iomab-B (I-131 apamistamab) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iomab-ACT for GeneTx and cell therapy conditioning, Actimab-A (CD33) and CLAG-M, Actimab-A (CD33) and Venetoclax, and Actimab-A (CD33) and Venetoclax with HMA. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 -SIRPa immunotherapy targeted radiotherapy; AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors; and Immedica pharma for licensed the rights to commercialize Iomab-B. The company is based in New York, New York.

Actinium Pharmaceuticals, Inc. News

04/18/24	Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
04/15/24	Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
04/01/24	Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting
06:18 AM	Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
03/15/24	High-Risk, High-Reward: Little-Known Biotech Stock ATNM Could Soar on Breakthrough Cancer Treatment
03/11/24	Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand
07:30 AM	Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings \| Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
02/25/24	7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
02/23/24	Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings \| Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
01/02/24	Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings \| Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
12/11/23	Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation
12/11/23	Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia
12/08/23	Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition
11/06/23	Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations
11/02/23	Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023
11/02/23	Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA Trial
10/31/23	Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
10/04/23	Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy
09/27/23	Actinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual Meeting
09/07/23	Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHO

ATNM Chatroom

mauryrosen Posted - 6 hours ago

$ATNM https://www.investors.com/news/technology/atnm-stock-craters-over-two-days-here-is-why-according-to-ceo-sandesh-seth/ I didn’t catch it the first time ….. but rereading I see where Seth says the company will file the BLA in the second half of this year.

Ferric Posted - 7 hours ago

$ATNM Anybody know what the short volume for the day was? Just one more day closure to our buyout people ✌️

gooddoggie Posted - 7 hours ago

$ATNM Scientists finally explain the existence of McNugget. No wonder his first name is Dennis.

janlukas Posted - 8 hours ago

$ATNM A question for the chat, for whoever will be kind enough to answer me. I read estimates of a possible buyout between 2 and 5 billion and even more. Given that I am an Atnm shareholder and therefore I believe in these values, however at this point I ask myself this question: If these valuations are really real I don't think anyone will ever be willing to pay 10-20 times the current price. On average I have seen a lot of buyouts but when things go well at best the price is three times the price of a stock, no more. Then perhaps there are also parameters for a buyout or can everyone freely decide the price?

beerjetz Posted - 8 hours ago

$ATNM Low volume manipulation propping up the stock price! 🚀🚀🚀🚀🤣🤣🤣🤣🤣

gooddoggie Posted - 9 hours ago

$ATNM 9.56. This is some kind of conspiracy probably from Russia.

Karmic Posted - 9 hours ago

$ATNM I'm guessing some more "options awards" are coming soon.

EFhutton420 Posted - 9 hours ago

$ATNM The SEC et al came by our offices today. We asked them to stay for tea.... https://www.youtube.com/watch?v=EZE0ii62kTo

AAVIE Posted - 9 hours ago

$ATNM

Theflash88 Posted - 10 hours ago

$ATNM A little more patience and hopefully you’ll be rewarded.

beerjetz Posted - 10 hours ago

$ATNM Just shaking out the weak hands, for the past 13 years! 🚀🚀🚀🚀🚀🚀🤣🤣🤣🤣🤣🤣🤣

EFhutton420 Posted - 10 hours ago

$ATNM carta de respuesta completa

TazDevil Posted - 10 hours ago

$ATNM worst POS of a so-called stock I've ever seen in my life. Seth is equally as bad. I've been stuck in this hell since it was $28/sh (my break even avg) ... for hundreds of thousands of $. So sick of it but obviously can't sell.

Mnur Posted - 10 hours ago

$ATNM https://www.investors.com/news/technology/biotech-stocks-big-pharma-radiopharmaceuticals-acquisitions/

gbtrade Posted - 11 hours ago

$ATNM Accumulation shenanigans, again. Guys, this is a typical institutional / hedge shake out of retail that happens EVERYTIME before a buyout occurs.

DWTW Posted - 11 hours ago

$ATNM PLEASE LET THIS THE DIP BEFORE THE BIG TAKE OFF!!!!!!!!

fwilkerson Posted - 11 hours ago

$ATNM okay

Kittinvestments Posted - 11 hours ago

$ATNM I’m not the type to do chart analysis… but what does this look to you? 😂 Seems like a change in trend, and we have not broken the upward movement.

HiIdontcareThx Posted - 12 hours ago

$ATNM love it. Sell me those cheapies cabbage boys!

gooddoggie Posted - 12 hours ago

$ATNM This is not a $6.77 stock.

greencheese500 Posted - 12 hours ago

$ATNM Whoa ... who bought 3000 Shares few minutes ago?

beerjetz Posted - 12 hours ago

$ATNM HELLOOOOOO RICHIII, DOOOOOOOOOOOWN!!!!!!!!!!!!!

gbtrade Posted - 13 hours ago

$ATNM Strange. I've been waiting 30 minutes to fill my Buy order at the Ask? 🤔 This MM really is trash. Where does he go? Constant smoke breaks?

Pickerbefore Posted - 13 hours ago

$ATNM MM playing games today as well as many other days. Trades taking place at Bid/Ask and not between them as they should. Slimeball for sure.

beerjetz Posted - 14 hours ago

$ATNM DOWNAGAIN!!!!!!!!!!!! BANKRUPTCY AS SOON!!!!!!!!! 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣

englishkaren Posted - 15 hours ago

$ATNM Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market https://www.investors.com/news/technology/biotech-stocks-big-pharma-radiopharmaceuticals-acquisitions/

gbtrade Posted - 16 hours ago

$ATNM DOW, XBI, BTC, almost everything tanking today. Has nothing to do with ATNM itself...

Investfaithfully Posted - 16 hours ago

$ATNM Dow down 600 pts!!!!!!!!

greencheese500 Posted - 18 hours ago

@Ormus @fwilkerson So it won't be a big deal for them to buy $ATNM just for $10B 😌

mich1282 Posted - 18 hours ago

$ATNM hopefully the proposed capital gains tax has Seth thinking sell in 24

Analyst Ratings

HC Wainwright & Co.	Buy	Apr 1, 24
Cantor Fitzgerald	Overweight	Apr 1, 24
HC Wainwright & Co.	Buy	Mar 26, 24
Maxim Group	Buy	Mar 19, 24
HC Wainwright & Co.	Buy	Mar 19, 24
HC Wainwright & Co.	Buy	Mar 11, 24
B. Riley Securities	Buy	Dec 11, 23
B. Riley Securities	Buy	Oct 3, 23
HC Wainwright & Co.	Buy	Sep 7, 23